Try our beta test site

Preventing Post-Stroke Depression

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2013 by University of Iowa.
Recruitment status was:  Active, not recruiting
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Robert G. Robinson, University of Iowa Identifier:
First received: October 29, 2003
Last updated: July 1, 2013
Last verified: July 2013
This study will evaluate the effectiveness of both drug and non-drug treatments in preventing depression after a stroke.

Condition Intervention Phase
Cerebrovascular Accident
Behavioral: Problem Solving Therapy
Drug: Escitalopram
Other: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prevention of Post-Stroke Depression - Treatment Strategy

Resource links provided by NLM:

Further study details as provided by University of Iowa:

Primary Outcome Measures:
  • Incidence of depressive disorders in the study population [ Time Frame: Measured at baseline, Week 6, and Months 3, 6, 9, 12, and 18 ]

Secondary Outcome Measures:
  • Functional Independence Measure [ Time Frame: Measured at baseline, at Week 6, and at Months 3, 6, 9, 12, and 18 ]
  • Stroke Impact Scale [ Time Frame: Measured at baseline, Week 6, and Months 3, 6, 9, 12, and 18 ]
  • Neurocognitive tests of executive functions and speed of information processing [ Time Frame: Measured at baseline and after 12 months ]

Estimated Enrollment: 201
Study Start Date: September 2002
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Problem Solving Therapy
Participants will receive problem solving therapy.
Behavioral: Problem Solving Therapy
Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
Experimental: 2. Escitalopram
Participants will receive escitalopram.
Drug: Escitalopram
Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
Other Name: Lexapro
Placebo Comparator: 3 Placebo
Participants will receive placebo.
Other: Placebo
Participants will receive a placebo pill.

Detailed Description:

The development of depression after a stroke is a serious condition that can have negative effects on thought, emotions, and overall daily functioning, particularly in the first year following the stroke. Evidence suggests that antidepressants may be used to prevent post-stroke depression. This study will treat nondepressed stroke patients with antidepressants or problem solving therapy (PST) to determine the most effective treatments for preventing depression.

Participants in this study will be randomly assigned to receive PST, escitalopram, or placebo (an inactive pill) for 12 months. Participants who display depressive symptoms for 2 weeks or more will be removed from the study. After 12 months, treatment will be discontinued and participants will be monitored for an additional 6 months.


Ages Eligible for Study:   31 Years to 89 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stroke within the last 120 days

Exclusion Criteria:

  • DSM (Diagnostic and Statistical Manual) IV criteria for major or minor depressive disorder
  • Heart, respiratory, kidney, or liver failure; severely disabling musculoskeletal disorder; or cancer
  • Diagnosis of neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Multiple System Atrophy, or Huntington's disease
  • Pre-existing dementia or aphasia with severe language comprehension deficits
  • Alcohol or substance abuse or dependence within the last 12 months
  • Recurrent unipolar or bipolar disorder prior to the stroke
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00071643

United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242-1000
United States, New York
Burke Rehabilitation Hospital
White Plains, New York, United States, 10605
Sponsors and Collaborators
University of Iowa
National Institute of Mental Health (NIMH)
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Robert G. Robinson, Professor, University of Iowa Identifier: NCT00071643     History of Changes
Other Study ID Numbers: R01MH065134 ( US NIH Grant/Contract Award Number )
Study First Received: October 29, 2003
Last Updated: July 1, 2013

Keywords provided by University of Iowa:

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists processed this record on March 27, 2017